206 related articles for article (PubMed ID: 30514666)
1. The Association Between Imaging Features of TSCT and the Expression of PD-L1 in Patients With Surgical Resection of Lung Adenocarcinoma.
Wu T; Zhou F; Soodeen-Lalloo AK; Yang X; Shen Y; Ding X; Shi J; Dai J; Shi J
Clin Lung Cancer; 2019 Mar; 20(2):e195-e207. PubMed ID: 30514666
[TBL] [Abstract][Full Text] [Related]
2. Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma.
Toyokawa G; Takada K; Okamoto T; Kawanami S; Kozuma Y; Matsubara T; Haratake N; Takamori S; Akamine T; Katsura M; Yamada Y; Shoji F; Baba S; Kamitani T; Oda Y; Honda H; Maehara Y
Ann Thorac Surg; 2017 Jun; 103(6):1750-1757. PubMed ID: 28347537
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
4. High Frequency of Programmed Death-ligand 1 Expression in Emphysematous Bullae-associated Lung Adenocarcinomas.
Toyokawa G; Takada K; Okamoto T; Kozuma Y; Matsubara T; Haratake N; Takamori S; Akamine T; Katsura M; Shoji F; Oda Y; Maehara Y
Clin Lung Cancer; 2017 Sep; 18(5):504-511.e1. PubMed ID: 28038981
[TBL] [Abstract][Full Text] [Related]
5. Computed Tomography Features of Lung Adenocarcinomas With Programmed Death Ligand 1 Expression.
Toyokawa G; Takada K; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Takamori S; Akamine T; Katsura M; Shoji F; Oda Y; Maehara Y
Clin Lung Cancer; 2017 Nov; 18(6):e375-e383. PubMed ID: 28385373
[TBL] [Abstract][Full Text] [Related]
6. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
[TBL] [Abstract][Full Text] [Related]
7. Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.
Takada K; Toyokawa G; Azuma K; Takamori S; Jogo T; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
In Vivo; 2018; 32(6):1541-1550. PubMed ID: 30348714
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients.
Takamori S; Takada K; Azuma K; Jogo T; Shimokawa M; Toyokawa G; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
Ann Surg Oncol; 2019 Jun; 26(6):1916-1924. PubMed ID: 30815801
[TBL] [Abstract][Full Text] [Related]
9. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
Jug R; Giovacchini CX; Liu B; Green CL; Clarke JM; Mahmood K; Pavlisko EN
J Am Soc Cytopathol; 2020; 9(6):485-493. PubMed ID: 32336671
[TBL] [Abstract][Full Text] [Related]
10. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M
J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126
[TBL] [Abstract][Full Text] [Related]
11. Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas.
Yoon J; Suh YJ; Han K; Cho H; Lee HJ; Hur J; Choi BW
Thorac Cancer; 2020 Apr; 11(4):993-1004. PubMed ID: 32043309
[TBL] [Abstract][Full Text] [Related]
12. Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma.
Yoon N; Kim J; Maeng LS; Ahn JH; Park ES
Anticancer Res; 2018 Oct; 38(10):6003-6008. PubMed ID: 30275232
[TBL] [Abstract][Full Text] [Related]
13. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y
J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415
[TBL] [Abstract][Full Text] [Related]
14. Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment.
Huynh TG; Morales-Oyarvide V; Campo MJ; Gainor JF; Bozkurtlar E; Uruga H; Zhao L; Gomez-Caraballo M; Hata AN; Mark EJ; Lanuti M; Engelman JA; Mino-Kenudson M
J Thorac Oncol; 2016 Nov; 11(11):1869-1878. PubMed ID: 27568346
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas.
Zito Marino F; Rossi G; Montella M; Botti G; De Cecio R; Morabito A; La Manna C; Ronchi A; Micheli M; Salatiello G; Micheli P; Rocco D; Accardo M; Franco R
Am J Surg Pathol; 2020 Mar; 44(3):378-386. PubMed ID: 31688140
[TBL] [Abstract][Full Text] [Related]
16. Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma.
Serra P; Petat A; Maury JM; Thivolet-Bejui F; Chalabreysse L; Barritault M; Ebran N; Milano G; Girard N; Brevet M
Lung Cancer; 2018 Apr; 118():62-68. PubMed ID: 29572005
[TBL] [Abstract][Full Text] [Related]
17. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
18. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
19. Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study.
Fujimoto D; Sato Y; Morimoto T; Uehara K; Ito M; Otsuka K; Nagata K; Sakanoue I; Hamakawa H; Nakagawa A; Takahashi Y; Imai Y; Tomii K
Clin Lung Cancer; 2018 Sep; 19(5):e667-e673. PubMed ID: 29844002
[TBL] [Abstract][Full Text] [Related]
20. Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.
Haratake N; Toyokawa G; Tagawa T; Kozuma Y; Matsubara T; Takamori S; Akamine T; Yamada Y; Oda Y; Maehara Y
Anticancer Res; 2017 Oct; 37(10):5713-5717. PubMed ID: 28982891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]